Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials!!

Clinical Trial 9785

Miami Beach, FL 33140


Study Summary:

A Phase III Clinical Trial for the Treatment of Alzheimer’s Disease is Now Enrolling Study Participants in the United States

The Gammaglobulin Alzheimer’s Partnership (GAP) Study is designed to evaluate the safety, efficacy, and tolerability of the investigational drug Intravenous Immune Globulin (IVIg) for the treatment of mild-to-moderate Alzheimer’s disease (AD). IVIg is a biologic agent with anti-inflammatory and immunomodulating properties; this study is being conducted to determine if IVIg can help slow the progression of AD symptoms.

Intravenous Immune Globulin (IVIg) has been approved and used successfully for over 20 years to treat a variety of autoimmune and immunodeficiency diseases. Since the late 1990s, there has been increasing evidence that immunotherapy targeting the amyloid beta (Aß) peptide can be used to treat Alzheimer’s disease (AD). IVIg has been found to contain anti-amyloid antibodies in various studies, although its mechanism of action in AD is still unknown.

Please Call 1-800-438-4380 and mention GAP studyjoomla stats


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.